ABTL-0812 is under clinical development by Ability Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ABTL-0812’s likelihood of approval (LoA) and phase transition for Endometrial Cancer took place on 29 Jun 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 29 Jun 2021 increased ABTL-0812’s LoA and PTSR for Squamous Non-Small Cell Lung Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ABTL-0812 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ABTL-0812 overview

ABTL-0812 is under development for the treatment of advanced solid tumors including  pancreatic cancer, biliary tract cancer, lung carcinoma, endometrial cancer, non-small cell lung cancer, adult and pediatric neuroblastoma, glioblastoma. It is administered orally. The drug candidate targets AKT, PI3K, dihydrofolate reductase (DHFR) and mTORC1/C2 and is developed based on membrane lipid therapy. It was also under development for the treatment of breast cancer and glioma.

Ability Pharmaceuticals overview

Ability Pharmaceuticals (Ability Pharma) is a clinical stage drug discovery and development biopharmaceutical company. The company discovers and develops human therapeutics for the treatment of cancer and other indications. Ability Pharma offers lead pipeline drug candidate such as ABTL0812, a new drug class of small molecules, developed for the treatment of lung and endometrial cancer. It offers treatment for lung, pancreatic and gynecological cancers. The company works in partnership with academic institutions to develop new drug candidates up to clinical proof of concept and later out-license them to pharmaceutical companies for development and marketing. Ability Pharma is headquartered in Barcelona City, Barcelona, Spain.

Quick View ABTL-0812 LOA Data

Report Segments
  • Innovator
Drug Name
  • ABTL-0812
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.